Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.50 |
| ▸ | SERPINC1 | P01008 | 2/20 | 0.40 |
| ▸ | BDNF | P23560 | 3/20 | 0.38 |
| ▸ | PTN | P21246 | 2/20 | 0.38 |
| ▸ | MDK | P21741 | 2/20 | 0.38 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.37 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.37 |
| ▸ | CCL2 | P13500 | 1/20 | 0.37 |
| ▸ | CCL5 | P13501 | 1/20 | 0.37 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.37 |
| ▸ | FGF1 | P05230 | 3/20 | 0.35 |
| ▸ | FGF2 | P09038 | 2/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16425611 | 0.97 | F10 (0.50) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL16425617 | 0.94 | F10 (0.48) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL16425620 | 0.93 | F10 (0.47) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL16425616 | 0.93 | F10 (0.49) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL16418343 | 0.90 | F10 (0.58) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL16425621 | 0.89 | F10 (0.47) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL16425607 | 0.86 | F10 (0.58) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL16425608 | 0.86 | F10 (0.58) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL17770817 | 0.85 | F10 (0.53) | F10SERPINC1BDNFPTNMDK | |
| SCHEMBL16425606 | 0.80 | F10 (0.52) | F10SERPINC1BDNFPTNMDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031866-A1 | PROCESS FOR THE PRODUCTION OF FONDAPARINUX SODIUM | SCINOPHARM TAIWAN, LTD. (TW) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031866-A1 | PROCESS FOR THE PRODUCTION OF FONDAPARINUX SODIUM | PF4, ABCC4, KCNH1 | F10 119/4885SERPINC1 190/4885BDNF 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.